IRIS
PALUMBO, Giuseppe Alberto Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.070
EU - Europa 7.524
AS - Asia 7.436
SA - Sud America 1.243
AF - Africa 826
Continente sconosciuto - Info sul continente non disponibili 524
OC - Oceania 20
AN - Antartide 1
Totale 31.644
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.566
SG - Singapore 3.741
RU - Federazione Russa 2.527
CN - Cina 1.938
IT - Italia 1.849
BR - Brasile 1.012
IE - Irlanda 967
UA - Ucraina 581
VN - Vietnam 565
CI - Costa d'Avorio 412
FR - Francia 382
CA - Canada 356
KR - Corea 328
SE - Svezia 253
BD - Bangladesh 190
DE - Germania 187
GB - Regno Unito 177
IN - India 176
NG - Nigeria 167
FI - Finlandia 117
AR - Argentina 91
NL - Olanda 81
HK - Hong Kong 80
MX - Messico 80
SN - Senegal 77
JP - Giappone 70
ES - Italia 68
PL - Polonia 68
BE - Belgio 55
ZA - Sudafrica 49
IQ - Iraq 48
CH - Svizzera 45
TR - Turchia 37
BJ - Benin 33
CZ - Repubblica Ceca 33
CO - Colombia 32
PK - Pakistan 30
EC - Ecuador 28
ID - Indonesia 28
UZ - Uzbekistan 27
AT - Austria 26
LT - Lituania 23
MA - Marocco 22
CL - Cile 20
VE - Venezuela 20
EG - Egitto 19
JO - Giordania 19
LB - Libano 19
AU - Australia 18
GR - Grecia 18
KE - Kenya 17
AE - Emirati Arabi Uniti 16
IR - Iran 16
DZ - Algeria 13
IL - Israele 13
MY - Malesia 13
PH - Filippine 13
JM - Giamaica 12
PE - Perù 12
PY - Paraguay 12
SA - Arabia Saudita 12
OM - Oman 10
TT - Trinidad e Tobago 10
BG - Bulgaria 9
RO - Romania 9
CR - Costa Rica 8
HN - Honduras 8
UY - Uruguay 8
AZ - Azerbaigian 7
EU - Europa 7
HR - Croazia 7
AL - Albania 6
KZ - Kazakistan 6
NP - Nepal 6
PS - Palestinian Territory 6
SV - El Salvador 6
ET - Etiopia 5
GT - Guatemala 5
KG - Kirghizistan 5
RS - Serbia 5
BO - Bolivia 4
CY - Cipro 4
DO - Repubblica Dominicana 4
MT - Malta 4
NI - Nicaragua 4
PR - Porto Rico 4
SI - Slovenia 4
AM - Armenia 3
BY - Bielorussia 3
GY - Guiana 3
LV - Lettonia 3
NO - Norvegia 3
PT - Portogallo 3
TN - Tunisia 3
AO - Angola 2
BB - Barbados 2
EE - Estonia 2
HU - Ungheria 2
KW - Kuwait 2
LU - Lussemburgo 2
Totale 31.098
Salva come PNG Salva come JPEG
Città #
Dallas 2.312
Singapore 2.273
Santa Clara 1.525
Moscow 1.129
San Jose 1.012
Dublin 939
Chandler 924
Houston 808
Ashburn 777
Chicago 546
Jacksonville 543
Hefei 454
Abidjan 412
Boardman 386
Catania 373
Seoul 325
Los Angeles 302
Lauterbourg 288
Beijing 274
Lawrence 248
Cambridge 245
Andover 241
Nanjing 212
Ho Chi Minh City 182
Toronto 169
Council Bluffs 159
New York 145
Civitanova Marche 132
Des Moines 129
Buffalo 125
Hanoi 122
Milan 113
São Paulo 110
Wilmington 108
Rome 105
San Mateo 90
Abuja 80
Dakar 77
Palermo 77
Lagos 76
Nanchang 72
Hong Kong 68
The Dalles 63
Florence 60
Lappeenranta 59
Montreal 59
Shenyang 58
Saint Petersburg 57
Warsaw 57
Orem 56
Tokyo 56
Hebei 54
Ottawa 54
Jiaxing 52
Brussels 51
Columbus 51
Grafing 46
Amsterdam 45
Brooklyn 45
Chennai 45
Munich 45
Washington 44
Changsha 43
Boston 41
Stockholm 41
Dong Ket 40
London 39
Seattle 39
Denver 38
Atlanta 36
Helsinki 35
Tianjin 34
Cotonou 33
Phoenix 33
Paris 32
Rio de Janeiro 31
Falls Church 29
Mexico City 29
Naples 29
San Francisco 29
Johannesburg 28
Poplar 28
Messina 27
Manchester 25
Mumbai 25
Turku 23
Haiphong 22
Kochi 22
Belo Horizonte 21
Bari 19
Frankfurt am Main 19
Baghdad 18
Bronte 18
Charlotte 18
Den Haag 18
Piscataway 18
Amman 17
Curitiba 17
Querétaro 17
Redondo Beach 17
Totale 20.792
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 300
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes 250
Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population 242
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 219
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 209
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 207
IGFBP-6 Alters Mesenchymal Stromal Cell Phenotype Driving Dasatinib Resistance in Chronic Myeloid Leukemia 206
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 203
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 202
A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells 189
Focus on Osteosclerotic Progression in Primary Myelofibrosis 189
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 185
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 182
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 179
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 173
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 171
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 171
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 170
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 168
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 166
Hedgehog signaling pathways in multiple myeloma 166
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 166
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 165
Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models 163
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients 163
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 162
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 161
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 161
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 160
A case of high-risk AML in a patient with advanced systemic mastocytosis 159
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 159
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 158
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 156
A physiological role for the neuropeptide luteinizing hormone-releasing hormone (LHRH) during the maturation of thymus Gland function 153
In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside 152
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 150
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 149
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 149
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 148
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 146
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) 146
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience 145
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 145
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 144
Correction to: Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models (Antioxidants, (2022), 11, 8, (1596), 10.3390/antiox11081596) 143
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 143
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 142
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 141
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 141
Renal extramedullary hematopoiesis as an epiphenomenon of bone marrow dysfunction in a patient with primary myelofibrosis: A rare case report 140
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 139
Multiple Myeloma in 2023 Ways: From Trials to Real Life 137
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 136
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma (Cell Death & Disease, (2019), 10, 10, (704), 10.1038/s41419-019-1959-5) 134
Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: A single-centre cohort pilot study 132
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 131
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 130
Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers 129
Terapia del mieloma multiplo 129
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia 129
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 129
Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation 129
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 128
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 128
Nuclear translocation of Heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells 128
Emangioma, plasmocitoma e mieloma multiplo del rachide 127
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients 126
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 126
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 125
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 125
Low serum levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in IFN-treated chronic myeloid leukemia (CML) patients 125
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 123
ANTITUMOR ACTIVITY OF BORTEZOMIB ALONE AND IN COMBINATION WITH TRAIL IN HUMAN ACUTE MYELOID LEUKEMIA C.M.S 123
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents 123
Emerging Therapeutic Approaches for Anemia in Myelofibrosis 122
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint 122
Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia 122
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 121
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 121
Emergencies in Hematology: Why, When and How I Treat? 119
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 119
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 119
Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity 118
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 118
Angiogenesis in acute myeloid leukemia 117
5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM 117
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 117
Anemia and blood transfusions in myelofibrosis: economic and organizational impact on Italian patients, caregivers and hospitals 116
Evaluation of taxol cytotoxicity on B-CLL cells in vitro 116
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 116
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality 115
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 114
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 114
IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis 113
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 112
Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia 112
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters 112
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 112
Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview 112
Chemotherapy extravasation: diagnosis, prevention and management 111
Totale 14.675
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.851
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.851
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.649 0 246 2 13 363 38 271 77 158 32 35 414
2022/20233.042 278 147 73 212 249 522 28 515 738 56 154 70
2023/20241.805 111 246 93 127 87 339 97 133 10 51 320 191
2024/20256.208 56 954 344 315 1.336 633 219 234 442 614 527 534
2025/202614.828 863 1.302 2.177 908 2.238 2.888 1.607 358 864 817 461 345
2026/2027575 393 182 0 0 0 0 0 0 0 0 0 0
Totale 31.644